Table 5.
Co-resistance of carbapenem non-susceptible K. pneumoniae isolates (n = 966) against other antibiotics
| Isolates from all laboratories | Isolates from laboratories that routinely test against the specified antibiotica | |||
|---|---|---|---|---|
| Tested against | Included isolates | Non-susceptible isolates, % (95%CI)b | Included isolates | Non-susceptible isolates, % (95%CI)b |
| Ampicillin/ Sulbactam | 871 | 93.0% (90.3, 95.0%) | c | c |
| Piperacillin/ Tazobactam | 950 | 90.7% (87.4, 93.2%) | c | c |
| Ceftazidime | 954 | 88.7% (85.8, 91.0%) | c | c |
| Cefotaxime | 908 | 88.3% (85.0, 91.0%) | c | c |
| Polymyxin/ Colistin | 435 | 13.3% (9.8, 17.9%) | 214 | 14.0% (8.8, 21.7%) |
| Tigecycline | 865 | 56.6% (51.0, 62.1%) | 709 | 55.6% (49.1, 61.8%) |
| Fosfomycin | 632 | 47.0% (40.6, 53.5%) | 319 | 46.7% (36.2, 57.5%) |
| Gentamicin | 960 | 57.8% (53.0, 62.4%) | c | c |
| Co-Trimoxazole | 961 | 62.7% (57.6, 67.6%) | c | c |
| Ciprofloxacin | 959 | 82.0% (78.4, 85.0%) | c | c |
| Nitrofurantoin | 313 | 82.7% (76.3, 87.7%) | 99 | 72.7% (60.0, 82.6%) |
R resistant, I intermediate, CI confidence interval
aAnalysis restricted to laboratories that test > 90% of isolates against the specified antibiotic
b95% CI calculated accounting for clustering by hospital
cAntibiotic is routinely tested in all laboratories (> 90% of all isolates tested)